Dermata Therapeutics Stock Performance
| DRMA Stock | USD 6.46 0.09 1.41% |
The firm shows a Beta (market volatility) of 0.9, which means possible diversification benefits within a given portfolio. Dermata Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Dermata Therapeutics is expected to follow. At this point, Dermata Therapeutics has a negative expected return of -0.24%. Please make sure to confirm Dermata Therapeutics' kurtosis, and the relationship between the value at risk and rate of daily change , to decide if Dermata Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Dermata Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's primary indicators remain somewhat strong which may send shares a bit higher in September 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 1.35 | Five Day Return (2.18) | Year To Date Return 364.46 | Ten Year Return (99.48) | All Time Return (99.48) |
Last Split Factor 1:10 | Last Split Date 2025-08-01 |
1 | Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results ... | 05/14/2025 |
2 | Dermata Faces Nasdaq Delisting Risk Over Bid Price - TipRanks | 05/16/2025 |
3 | Head-To-Head Contrast Xencor vs. Dermata Therapeutics | 05/23/2025 |
4 | Pre-market Movers STSS, SGMT, NIVF, OGEN... - RTTNews | 06/04/2025 |
5 | Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for ... | 07/08/2025 |
6 | What analysts say about Dermata Therapeutics Inc. Equity Warrant stock - Overwhelming profit margins - Jammu Links News | 07/18/2025 |
7 | What drives Dermata Therapeutics Inc. Equity Warrant stock price - Superior capital gains - Autocar Professional | 07/23/2025 |
8 | What are Dermata Therapeutics Inc. companys key revenue drivers - AI Powered Tips With High Returns - jammulinksnews.com | 07/31/2025 |
| Begin Period Cash Flow | 7.4 M |
Dermata Therapeutics Relative Risk vs. Return Landscape
If you would invest 794.00 in Dermata Therapeutics on May 12, 2025 and sell it today you would lose (148.00) from holding Dermata Therapeutics or give up 18.64% of portfolio value over 90 days. Dermata Therapeutics is currently does not generate positive expected returns and assumes 4.1508% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Dermata, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Dermata Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Dermata Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Dermata Therapeutics, and traders can use it to determine the average amount a Dermata Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0582
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | DRMA |
Estimated Market Risk
| 4.15 actual daily | 37 63% of assets are more volatile |
Expected Return
| -0.24 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Dermata Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Dermata Therapeutics by adding Dermata Therapeutics to a well-diversified portfolio.
Dermata Therapeutics Fundamentals Growth
Dermata Stock prices reflect investors' perceptions of the future prospects and financial health of Dermata Therapeutics, and Dermata Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Dermata Stock performance.
| Return On Equity | -2.06 | ||||
| Return On Asset | -0.96 | ||||
| Current Valuation | (5.6 M) | ||||
| Shares Outstanding | 637.81 K | ||||
| Price To Book | 0.56 X | ||||
| EBITDA | (12.29 M) | ||||
| Net Income | (12.29 M) | ||||
| Cash And Equivalents | 10.63 M | ||||
| Cash Per Share | 1.05 X | ||||
| Total Debt | 1.97 M | ||||
| Current Ratio | 8.07 X | ||||
| Book Value Per Share | 12.10 X | ||||
| Cash Flow From Operations | (11.16 M) | ||||
| Earnings Per Share | (14.20) X | ||||
| Market Capitalization | 4.12 M | ||||
| Total Asset | 3.53 M | ||||
| Retained Earnings | (65.68 M) | ||||
| Working Capital | 1.56 M | ||||
About Dermata Therapeutics Performance
By analyzing Dermata Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Dermata Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Dermata Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Dermata Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | -3.5 K | -3.3 K | |
| Return On Capital Employed | -8 K | -7.6 K | |
| Return On Assets | -3.5 K | -3.3 K | |
| Return On Equity | (7.87) | (7.48) |
Things to note about Dermata Therapeutics performance evaluation
Checking the ongoing alerts about Dermata Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Dermata Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Dermata Therapeutics generated a negative expected return over the last 90 days | |
| Dermata Therapeutics has high historical volatility and very poor performance | |
| Dermata Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (12.29 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Dermata Therapeutics currently holds about 10.63 M in cash with (11.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.05. | |
| Dermata Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 18.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: What are Dermata Therapeutics Inc. companys key revenue drivers - AI Powered Tips With High Returns - jammulinksnews.com |
- Analyzing Dermata Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Dermata Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Dermata Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Dermata Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Dermata Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Dermata Therapeutics' stock. These opinions can provide insight into Dermata Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Dermata Stock analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |